









市场行情
/
股票
/
nasdaq-vtvt
/

vTv Therapeutics Inc

VTVT

37.764USD

+1.754+4.87%

交易中（美东）报价延迟15分钟

148.72M总市值

亏损市盈率 TTM



vTv Therapeutics Inc

37.764

+1.754+4.87%

概览公司财务分析

概览

公司

财务

分析

关于 vTv Therapeutics Inc 公司

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

vTv Therapeutics Inc简介



公司代码VTVT

公司名称vTv Therapeutics Inc

上市日期Jul 30, 2015

CEOSekhri (Paul Jai)

员工数量23

证券类型Ordinary Share

年结日Jul 30

公司地址3980 Premier Dr

城市HIGH POINT

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编27265

电话13368410300

网址https://vtvtherapeutics.com/

公司代码VTVT

上市日期Jul 30, 2015

CEOSekhri (Paul Jai)

vTv Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Paul Jai Sekhri

Chairman of the Board, President, Chief Executive Officer

5.00K

-82.80%

Dr. Anne M. Phillips, M.D.

Independent Director

2.15K

Dr. Raymond Cheong, M.D., Ph.D.

Independent Director

1.83K

Mr. Richard S. (Rich) Nelson

Executive Vice President - Corporate Development, Director

Dr. Srinivas Akkaraju, M.D., Ph.D.

Independent Director

-100.00%

Mr. Fahed Al Marzooqi, M.D.

Independent Director

Mr. Burns Mcclellan

Investor Relations

Dr. Michael Tung, M.D.

Executive Vice President, Chief Financial Officer

Mr. Daniel (Dan) Spiegelman

Director

名称

名称/职务

职务

持股

持股变动

Mr. Paul Jai Sekhri

Chairman of the Board, President, Chief Executive Officer

5.00K

-82.80%

Dr. Anne M. Phillips, M.D.

Independent Director

2.15K

Dr. Raymond Cheong, M.D., Ph.D.

Independent Director

1.83K

Mr. Richard S. (Rich) Nelson

Executive Vice President - Corporate Development, Director

Dr. Srinivas Akkaraju, M.D., Ph.D.

Independent Director

-100.00%

Mr. Fahed Al Marzooqi, M.D.

Independent Director

收入明细

FY2023

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

0.00

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月5日周五

持股股东

股东类型

持股股东

占比

MacAndrews & Forbes Holdings, Inc.

23.18%

Samsara BioCapital, LLC

7.58%

Trails Edge Capital Partners LP

5.87%

Fidelity Management & Research Company LLC

4.90%

Invus Public Equities Advisors, LLC

4.14%

其他

54.33%

持股股东

占比

MacAndrews & Forbes Holdings, Inc.

23.18%

Samsara BioCapital, LLC

7.58%

Trails Edge Capital Partners LP

5.87%

Fidelity Management & Research Company LLC

4.90%

Invus Public Equities Advisors, LLC

4.14%

其他

54.33%

股东类型

持股股东

占比

Holding Company

23.18%

Investment Advisor

16.48%

Venture Capital

7.58%

Hedge Fund

4.34%

Investment Advisor/Hedge Fund

0.75%

Individual Investor

0.42%

其他

47.24%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

1.15M

29.13%

+562.26K

2025Q2

1.51M

57.66%

-17.51K

2025Q1

1.53M

60.03%

+1.63K

2024Q4

1.51M

61.92%

-7.51K

2024Q3

1.49M

61.31%

+181.69K

2024Q2

1.29M

53.13%

+308.00

2024Q1

1.68M

72.07%

+129.32K

2023Q4

1.40M

68.78%

-52.49K

2023Q3

1.41M

69.35%

-49.61K

2023Q2

1.40M

81.32%

+323.67K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

MacAndrews & Forbes Holdings, Inc.

912.98K

34.88%

Apr 01, 2025

Samsara BioCapital, LLC

312.78K

11.95%

+106.00K

+51.26%

Sep 22, 2025

Trails Edge Capital Partners LP

231.00K

8.83%

+231.00K

Aug 29, 2025

Fidelity Management & Research Company LLC

178.20K

6.81%

Jun 30, 2025

Baker Bros. Advisors LP

148.31K

5.67%

+51.00K

+52.41%

Sep 03, 2025

The Vanguard Group, Inc.

43.17K

1.65%

+1.62K

+3.89%

Jun 30, 2025

Geode Capital Management, L.L.C.

12.87K

0.49%

+229.00

+1.81%

Jun 30, 2025

Northern Trust Investments, Inc.

15.29K

0.58%

-339.00

-2.17%

Jun 30, 2025

Millennium Management LLC

15.04K

0.57%

+15.04K

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.01%

iShares Core S&P Total U.S. Stock Market ETF

iShares Micro-Cap ETF

占比0.01%

iShares Core S&P Total U.S. Stock Market ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

公告日期

类型

比率

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

常见问题

vTv Therapeutics Inc的前五大股东是谁？



vTv Therapeutics Inc 的前五大股东如下：
MacAndrews & Forbes Holdings, Inc.持有股份：912.98K，占总股份比例：34.88%。
Samsara BioCapital, LLC持有股份：312.78K，占总股份比例：11.95%。
Trails Edge Capital Partners LP持有股份：231.00K，占总股份比例：8.83%。
Fidelity Management & Research Company LLC持有股份：178.20K，占总股份比例：6.81%。
Baker Bros. Advisors LP持有股份：148.31K，占总股份比例：5.67%。